Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 0.52 |
| ▸ | CYP26A1 | O43174 | 7/20 | 0.48 |
| ▸ | RARB | P10826 | 5/20 | 0.47 |
| ▸ | RARG | P13631 | 5/20 | 0.47 |
| ▸ | RARA | P10276 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.47 |
| ▸ | BLVRB | P30043 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5178238 | 0.88 | RARA (0.48) | CYP3A4CYP26A1RARBRARGRARA | |
| SCHEMBL5180319 | 0.87 | RARB (0.59) | CYP3A4CYP26A1RARBRARGRARA | |
| SCHEMBL17049073 | 0.86 | CYP3A4 (0.54) | CYP3A4CYP26A1RARBRARGRARA | |
| SCHEMBL17049087 | 0.83 | CYP3A4 (0.61) | CYP3A4CYP26A1RARBRARGRARA | |
| SCHEMBL17049072 | 0.80 | CYP3A4 (0.46) | CYP3A4CYP26A1RARBRARGRARA | |
| SCHEMBL17049081 | 0.80 | CYP3A4 (0.44) | CYP3A4CYP26A1RARBRARGRARA | |
| SCHEMBL9118094 | 0.80 | RARA (0.59) | CYP3A4CYP26A1RARBRARGRARA | |
| SCHEMBL20398880 | 0.79 | CYP3A4 (0.59) | CYP3A4CYP26A1RARBRARGRARA | |
| SCHEMBL20398885 | 0.77 | CYP3A4 (0.57) | CYP3A4CYP26A1RARBRARGRARA | |
| SCHEMBL20398882 | 0.77 | RXRA (0.54) | CYP3A4CYP26A1RARBRARGRARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260103445-A1 | Compositions Comprising a Retinoid X Receptor (RXR) Agonist, a Retinoic Acid Receptor (RAR) Agonist, or a Dual RXR/RAR Agonist | UNIV ARIZONA STATE (US) | 2026-04-16 | — | — | US | disclosed |
| US-12540121-B2 | Compositions comprising a retinoid X receptor (RXR) agonist, a retinoic acid receptor (RAR) agonist, or a dual RXR/RAR agonist | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2026-02-03 | — | — | US | disclosed |
| US-20220259157-A1 | Compositions Comprising a Retinoid X Receptor (RXR) Agonist, a Retinoic Acid Receptor (RAR) Agonist, or a Dual RXR/RAR Agonist | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2022-08-18 | — | — | US | disclosed |
| WO-2020263960-A1 | COMPOSITIONS COMPRISING A RETINOID X RECEPTOR (RXR) AGONIST, A RETINOIC ACID RECEPTOR (RAR) AGONIST, OR A DUAL RXR/RAR AGONIST | WAGNER CARL (US) | 2020-12-30 | — | — | WO | disclosed |
| US-10005741-B2 | Therapeutic compounds | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2018-06-26 | — | — | US | disclosed |
| US-20180141921-A1 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2018-05-24 | — | — | US | disclosed |
| US-20180141921-A1 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2018-05-24 | — | — | US | disclosed |
| US-9908856-B2 | Therapeutic compounds | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2018-03-06 | — | — | US | disclosed |
| US-9908856-B2 | Therapeutic compounds | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2018-03-06 | — | — | US | disclosed |
| US-20170008859-A1 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2017-01-12 | — | — | US | disclosed |
| US-20170008859-A1 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2017-01-12 | — | — | US | disclosed |
| WO-2015130973-A1 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2015-09-03 | — | — | WO | disclosed |
| WO-2015130973-A1 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2015-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12540121-B2 | Compositions comprising a retinoid X receptor (RXR) agonist, a retinoic acid receptor (RAR) agonist, or a dual RXR/RAR agonist | RXRA, RXRB, RARA | CYP3A4 1553/4885CYP26A1 114/4885RARB 5/4885 |
| US-20220259157-A1 | Compositions Comprising a Retinoid X Receptor (RXR) Agonist, a Retinoic Acid Receptor (RAR) Agonist, or a Dual RXR/RAR Agonist | RXRA, RARA, RXRG | CYP3A4 1455/4885CYP26A1 294/4885RARB 6/4885 |
| US-20170008859-A1 | THERAPEUTIC COMPOUNDS | IAPP, PARK7, NLN | CYP3A4 3854/4885CYP26A1 3205/4885RARB 379/4885 |
| US-20180141921-A1 | THERAPEUTIC COMPOUNDS | IAPP, PARK7, NLN | CYP3A4 3854/4885CYP26A1 3205/4885RARB 379/4885 |
| US-10005741-B2 | Therapeutic compounds | IAPP, PARK7, NLN | CYP3A4 3854/4885CYP26A1 3205/4885RARB 379/4885 |
| US-20260103445-A1 | Compositions Comprising a Retinoid X Receptor (RXR) Agonist, a Retinoic Acid Receptor (RAR) Agonist, or a Dual RXR/RAR Agonist | RXRA, RXRG, RXRB | CYP3A4 835/4885CYP26A1 61/4885RARB 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.